Cleopatra Hospital SAE

Cleopatra Hospital SAE has a liquidity ratio of 1.36, indicating a moderate level of liquidity. The company's price-to-book ratio is 3.93, which is relatively high, suggesting that the market is valuing the company's equity at a premium. The company's price-to-earnings ratio is 52.58, indicating that investors are willing to pay a high price for each dollar of earnings.

In terms of profitability, Cleopatra Hospital SAE has a return on equity of 7.47% and a return on assets of 3.48%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high returns on equity and assets. The company's operating income margin is 23.4%, and its net income margin is 15.4%, which are key indicators of its profitability.

The company's revenue is primarily concentrated in its core hospital services, with no significant diversification into other segments. Geographically, the company's operations are centered in Egypt, and there is no indication of significant international expansion or diversification.

Cleopatra Hospital SAE's growth trajectory is expected to be positive, with analysts providing a mean price target of 14.53 EGP, which is significantly higher than the current market price of 6.61 EGP. The company's revenue has shown a consistent growth pattern, and the positive analyst sentiment suggests a favorable outlook for the company's future performance.

The company faces a medium level of liquidity risk, as indicated by the risk assessment. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully. The dilution risk is assessed as low, and there are no significant adjustments applied to the company's valuations that would indicate a high dilution potential.

Recent events and filings do not indicate any major changes or risks for Cleopatra Hospital SAE. The company's financial health appears stable, with a strong balance sheet and positive analyst recommendations. There are no recent transcripts or filings that suggest significant operational or financial challenges.

Revenue grew 29.8% annually over four years, demonstrating strong top-line expansion in the healthcare sector.

Net margin of 15.4% ranks in the top quartile, outperforming the 4.2% cohort median.

Cash conversion ratio of 2.05 is above the 1.36 cohort median, suggesting robust cash generation relative to earnings.

Free cash flow turned negative, reaching -1.76 billion EGP in FY2025, signaling severe cash burn.

Long-term debt surged to 2.46 billion EGP in FY2025, reflecting aggressive leverage expansion.

The company faces high credit risk, indicating potential difficulties in meeting financial obligations.

Revenue EGP 1.91B, +20,1% YoY; Operating income −26,3% YoY.

• ▍Revenue EGP 1.91B, +20,1% YoY
• ▍Operating income −26,3% YoY
• ▍Net income −45,6% YoY
• ▍Free cash flow −44,0% YoY
• ▍Net margin 5.5%

Revenue EGP 1.94B, +32,8% YoY; Operating income +41,5% YoY.

• ▍Revenue EGP 1.94B, +32,8% YoY
• ▍Operating income +41,5% YoY
• ▍Net income +29,8% YoY
• ▍Free cash flow +58,5% YoY
• ▍Net margin 13.9%

Revenue EGP 1.76B, +48,0% YoY; Operating income +87,5% YoY.

• ▍Revenue EGP 1.76B, +48,0% YoY
• ▍Operating income +87,5% YoY
• ▍Net income +75,2% YoY
• ▍Free cash flow −9 666,1% YoY
• ▍Net margin 14.2%

Revenue EGP 7.23B, +33,3% YoY; Operating income +28,1% YoY.

• ▍Revenue EGP 7.23B, +33,3% YoY
• ▍Operating income +28,1% YoY
• ▍Net income +13,9% YoY
• ▍Free cash flow +10,6% YoY
• ▍Net margin 11.4%

Revenue EGP 5.42B, +50,8% YoY; Operating income +78,7% YoY.

• ▍Revenue EGP 5.42B, +50,8% YoY
• ▍Operating income +78,7% YoY
• ▍Net income +73,0% YoY
• ▍Free cash flow −646,4% YoY
• ▍Net margin 13.3%

Revenue EGP 3.60B, +37,5% YoY; Operating income +46,6% YoY.

• ▍Revenue EGP 3.60B, +37,5% YoY
• ▍Operating income +46,6% YoY
• ▍Net income +28,4% YoY
• ▍Free cash flow −1 034,2% YoY
• ▍Net margin 11.6%

Revenue EGP 2.61B, +2,6% YoY; Operating income −12,8% YoY.

• ▍Revenue EGP 2.61B, +2,6% YoY
• ▍Operating income −12,8% YoY
• ▍Net income −15,9% YoY
• ▍Free cash flow −89,3% YoY
• ▍Net margin 12.5%

Revenue EGP 2.55B; Operating income EGP 509.5M.

• ▍Revenue EGP 2.55B
• ▍Operating income EGP 509.5M
• ▍Net margin 15.2%